Eli Lilly Initiates the World’s First Clinical Study to Evaluate the Potential of COVID-19 Antibody Treatment in Humans

 Eli Lilly Initiates the World’s First Clinical Study to Evaluate the Potential of COVID-19 Antibody Treatment in Humans

Shots:

  • Eli Lilly reported that first patients have been dosed in a P-I study of LY-CoV555, the first Ab emerge from the collaboration b/w Lilly & AbCellera to create Ab therapies against COVID-19. The P-I J2W-MC-PYAA study aims to evaluate the safety, tolerability, PK/PD of LY-CoV555 following a single dose administered to participants hospitalized for COVID-19
  • Post-P-I results, Lilly anticipates the assessment of LY-CoV555 in non-hospitalized COVID-19 patients.  The company plans to study the drug in a preventative setting, focusing on vulnerable patient populations who are not optimal candidates for vaccines
  • In the month-end, Lilly will review the results of the P-I J2W-MC-PYAA study and intend to initiate broader efficacy trials. Lilly plans to make several thousand doses of LY-CoV555 by the end of the year

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post